Skip to main content
. 2011 May;2(5):576–584. doi: 10.1177/1947601911412375

Figure 4.

Figure 4.

Ranpirnase suppresses mesothelioma (MM) growth in vivo and extends animal survival. (A) The growth of PPM-Mill and REN xenografts was monitored by IVIS weekly. Representative mice tumor imaging 1 week before treatment (white arrow) and 1 week after (black arrow) and 4 weeks (gray arrow) after the end of treatment is shown. (B) Quantitative analysis of bioluminescence photon counts as a measure of tumor growth during the entire experiment. Ranpirnase (ONC) treatment nearly suppressed tumor growth after 2 weeks in both groups, and the reduction in tumor size was evident even 4 weeks after discontinuation of ranpirnase treatment. Open symbol curve = vehicle control mice; closed symbol curve = ranpirnase (2.5 µg/g body weight). The horizontal line above the curves indicates the interval of ranpirnase (ONC) administration. (C) Kaplan-Meier survival curves of ranpirnase (ONC)–treated mice show median survival values of 136 days (PPM-Mill) and 153 days (REN) compared to the vehicle control mice median survival of 109 days (PPM-Mill) and 101.5 days (REN). Significance: P < 0.01.